{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:50:18Z","timestamp":1776185418178,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["336431"],"award-info":[{"award-number":["336431"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014578","name":"Terveyden ja hyvinvoinnin laitos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014578","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128347","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:10:38Z","timestamp":1771942238000},"page":"128347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Immune responses following sequential mRNA booster doses targeting the SARS-CoV-2 omicron variants in immunocompromised individuals \u2013 A 3.5-year follow-up"],"prefix":"10.1016","volume":"77","author":[{"given":"Nina","family":"Ekstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oona","family":"Liedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saimi","family":"Vara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anu","family":"Haveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Solastie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Heikkil\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuija","family":"Leino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilkka","family":"Helanter\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arto A.","family":"Palmu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanna","family":"Nohynek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merit","family":"Melin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128347_bb0005","doi-asserted-by":"crossref","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 584:430\u20136. doi:https:\/\/doi.org\/10.1038\/s41586-020-2521-4.","DOI":"10.1038\/s41586-020-2521-4"},{"key":"10.1016\/j.vaccine.2026.128347_bb0010","doi-asserted-by":"crossref","unstructured":"Semenzato L, Botton J, Drouin J, Baricault B, Bertrand M, Jabagi M-J, et al. Characteristics associated with the residual risk of severe COVID-19 after a complete vaccination schedule: a cohort study of 28 million people in France. The Lancet Regional Health - Europe 19:100441. doi:https:\/\/doi.org\/10.1016\/j.lanepe.2022.100441.","DOI":"10.1016\/j.lanepe.2022.100441"},{"key":"10.1016\/j.vaccine.2026.128347_bb0015","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1182\/bloodadvances.2021006333","article-title":"Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis","volume":"6","author":"Teh","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.vaccine.2026.128347_bb0020","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2665-9913(24)00065-1","article-title":"Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial","volume":"6","author":"Goodyear","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.vaccine.2026.128347_bb0025","doi-asserted-by":"crossref","unstructured":"Widhani A, Hasibuan AS, Rismawati R, Maria S, Koesnoe S, Hermanadi MI, et al. Efficacy, immunogenicity, and safety of COVID-19 vaccines in patients with autoimmune diseases: a systematic review and meta-analysis. Vaccines (Basel) 11:1456. doi:https:\/\/doi.org\/10.3390\/vaccines11091456.","DOI":"10.3390\/vaccines11091456"},{"key":"10.1016\/j.vaccine.2026.128347_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13926","article-title":"Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: a systematic review and meta-analysis","volume":"24","author":"Meshram","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128347_bb0035","doi-asserted-by":"crossref","unstructured":"Bj\u00f8rlykke KH, \u00d8rbo HS, Tveter AT, Jyssum I, Sexton J, Tran TT, et al. Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study. Lancet Rheumatol 5:e36\u201346. doi:https:\/\/doi.org\/10.1016\/S2665-9913(22)00330-7.","DOI":"10.1016\/S2665-9913(22)00330-7"},{"key":"10.1016\/j.vaccine.2026.128347_bb0040","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S2468-1253(22)00005-X","article-title":"COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study","volume":"7","author":"Alexander","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2026.128347_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105385","article-title":"Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID","volume":"109","author":"Chen","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2026.128347_bb0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10096-023-04701-x","article-title":"Longevity of the humoral and cellular responses after SARS-CoV-2 booster vaccinations in immunocompromised patients","volume":"43","author":"Oyaert","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128347_bb0055","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/S1473-3099(23)00357-2","article-title":"Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients","volume":"23","author":"Solera","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128347_bb0060","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1093\/cid\/ciac557","article-title":"Antibody and T-cell responses 6 months after Coronavirus disease 2019 messenger RNA-1273 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant","volume":"76","author":"Sanders","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128347_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.858399","article-title":"Evaluation of humoral and cellular responses in SARS-CoV-2 mRNA vaccinated immunocompromised patients","volume":"13","author":"Oyaert","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128347_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1247129","article-title":"Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals","volume":"14","author":"Szekanecz","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128347_bb0075","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/14760584.2022.2035222","article-title":"COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies","volume":"21","author":"Di Fusco","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128347_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105577","article-title":"Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of omicron-adapted booster doses","volume":"113","author":"Ciabattini","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2026.128347_bb0085","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162192","article-title":"Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity","volume":"133","author":"Aguilar-Bretones","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2026.128347_bb0090","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMc2211055","article-title":"Immune imprinting and protection against repeat reinfection with SARS-CoV-2","volume":"387","author":"Chemaitelly","year":"2022","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2026.128347_bb0095","article-title":"Hybrid immunity improves the immune response after the fourth COVID-19 vaccine dose in individuals with medical conditions predisposing to severe COVID-19","volume":"12","author":"Ekstr\u00f6m","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128347_bb0100","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.679","article-title":"Impaired immunity and high attack rates caused by SARS-CoV-2 variants among vaccinated long-term care facility residents","volume":"10","author":"Obach","year":"2022","journal-title":"Immunity, Inflammation and Disease"},{"key":"10.1016\/j.vaccine.2026.128347_bb0105","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.01131-21","article-title":"A highly sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA, and IgM class antibodies","volume":"9","author":"Solastie","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.vaccine.2026.128347_bb0110","unstructured":"WHO Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody 2025 https:\/\/www.who.int\/publications\/m\/item\/WHO-BS-2020.2403 (accessed November 26, 2025)."},{"key":"10.1016\/j.vaccine.2026.128347_bb0115","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.11.2000266","article-title":"Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020","volume":"25","author":"Haveri","year":"2020","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2026.128347_bb0120","doi-asserted-by":"crossref","unstructured":"Haveri A, Ekstr\u00f6m N, Solastie A, Virta C, \u00d6sterlund P, Isosaari E, et al. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol 51:3202\u201313. doi:https:\/\/doi.org\/10.1002\/eji.202149535.","DOI":"10.1002\/eji.202149535"},{"key":"10.1016\/j.vaccine.2026.128347_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1146500","article-title":"T cell immunity following COVID-19 vaccination in adult patients with primary antibody deficiency - a 22-month follow-up","volume":"14","author":"Hurme","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128347_bb0130","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128347_bb0135","article-title":"Omicron BA.4\/BA.5 escape neutralizing immunity elicited by BA.1 infection","volume":"3","author":"Khan","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128347_bb0140","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","article-title":"Antibody evasion by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4 and BA.5","volume":"608","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128347_bb0145","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 omicron BA.4 and BA.5 from vaccine and BA.1 serum","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2026.128347_bb0150","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-84138-0","article-title":"Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections","volume":"15","author":"Suntronwong","year":"2025","journal-title":"Sci Rep"},{"issue":"8047","key":"10.1016\/j.vaccine.2026.128347_bb0155","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","article-title":"Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1","volume":"637","author":"Jian","year":"2024","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128347_bb0160","article-title":"Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine","volume":"4","author":"Wang","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.vaccine.2026.128347_bb0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41421-025-00800-5","article-title":"Multiple infections with omicron variants increase breadth and potency of omicron-specific neutralizing antibodies","volume":"11","author":"You","year":"2025","journal-title":"Cell Discov"},{"key":"10.1016\/j.vaccine.2026.128347_bb0170","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.immuni.2024.01.017","article-title":"SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase","volume":"57","author":"Srivastava","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2026.128347_bb0175","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2213907","article-title":"Antibody response to omicron BA.4\u2013BA.5 bivalent booster","volume":"388","author":"Wang","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.vaccine.2026.128347_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.101121","article-title":"Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study","volume":"48","author":"\u00d8rbo","year":"2025","journal-title":"The Lancet Regional Health \u2013 Europe"},{"key":"10.1016\/j.vaccine.2026.128347_bb0185","doi-asserted-by":"crossref","unstructured":"Ferreira VH, Keith B, Mavandadnejad F, Ferro A, Marocco S, Amidpour G, et al. Longitudinal innate and heterologous adaptive immune responses to SARS-CoV-2 JN.1 in transplant recipients with prior Omicron infection: limited neutralization but robust CD4+ T-cell activity. Transplant Infect Dis:e70067. doi:https:\/\/doi.org\/10.1111\/tid.70067.","DOI":"10.1111\/tid.70067"},{"key":"10.1016\/j.vaccine.2026.128347_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1099246","article-title":"Persistent T cell-mediated immune responses against omicron variants after the third COVID-19 mRNA vaccine dose","volume":"14","author":"Belik","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128347_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106261","article-title":"Comparative effectiveness of bivalent BA.4\u20135 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: a nationwide cohort study","volume":"89","author":"Gram","year":"2024","journal-title":"J Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:49:23Z","timestamp":1776181763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26001556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"alternative-id":["S0264410X26001556"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128347","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune responses following sequential mRNA booster doses targeting the SARS-CoV-2 omicron variants in immunocompromised individuals \u2013 A 3.5-year follow-up","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128347","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128347"}}